Herein, the in-detail pharmacological profile of AA, including androgen signaling, mechanism of action of AA, mechanism of AA resistance, pharmacokinetics, latest clinical findings...
AstraZeneca announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote Zytiga (abiraterone...
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone...
The FDA has expanded the approved use of Zytiga (abiraterone acetate) from Janssen Biotech, to treat men with late-stage (metastatic)...
Background: Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of Zejula (niraparib) + Zytiga (abiraterone acetate) in the form of a dual action tablet (DAT) plus prednisolone, for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR)+ gene alterations.
Phase III trial of Xofigo (radium-223 dichloride (radium-223)) in combination with abiraterone acetate and prednisone/prednisolone in prostate cancer.
A Phase III study of Zytiga (abiraterone acetate), from Janssen, plus prednisone for the treatment of asymptomatic or mildly symptomatic...
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer...
Purpose of review: The aim of this article is to review the role of prostate radiotherapy in the multimodal management of newly diagnosed metastatic hormone naïve prostate cancer.